Keywords
How to Cite
Abstract
This review article addresses the benefit of the use of SLGT2 inhibitors in patients with heart failure, a chronic and complex pathology associated with several comorbidities. The objective is to analyze the efficacy of pharmacological therapy with the use of SLGT2 inhibitors, considering the benefits both in the control and progression of the disease and in hospitalizations and mortality With regard to the results and discussion of this article, SLGT2 inhibitors have been shown to be effective in reducing the risk of cardiovascular death or hospitalization for heart failure. In addition to offering the benefit of reducing oxidative stress and slows down the progression of kidney disease caused by hyperglycemia, especially in diabetic patients, which contributes to an improvement in the cardiovascular outcomes of these patients. . In addition to offering the benefit of reducing oxidative stress and slows down the progression of kidney disease caused by hyperglycemia, especially in diabetic patients, which contributes to an improvement in the cardiovascular outcomes of these patients. Studies have shown that these drugs play a significant role in reducing the risk of hospitalizations due to heart failure, consolidating themselves as an essential therapeutic strategy in the prevention of new cases of this condition.
References
Anker, S. D., Butler, J., Filippatos, G., et al. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine, 385(16), 1451–1461.
BHATT, D.L. et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, v. 384, n. 2, p. 117-128, jan. 2021.
CARUBELLI, V. et al. Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure. ESC Heart Failure, v. 8, p. 1944–53, 2021.
CONRAD, N. et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. The Lancet, v. 391, n. 10120, p. 572-580, 2018.
Lambers Heerspink, H. J. et al. Dapagliflozin in patients with chronic kidney disease and type 2 diabetes. The New England Journal of Medicine, v. 380, n. 24, p. 2307-2319, 2019.
LOPASCHUK, G.D.; VERMA, S. Mechanisms of cardiovascular benefits of sodium glucose Co-transporter 2 (SGLT2) inhibitors. JACC Basic Transl Sci, v. 5, p. 632–644, 2020.
McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. The New England Journal of Medicine, v. 381, n. 21, p. 1995-2008, 2019.
MESQUITA, E. T.; JORGE, A. J. L. Insuficiência cardíaca com fração de ejeção normal: novos critérios diagnósticos e avanços fisiopatológicos. Arquivos Brasileiros de Cardiologia, v. 93, n. 2, p. 180–187, ago. 2009.
NAIR, N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Revista de Medicina Cardiovascular, v. 21, n. 4, p. 531-540, dez. 2020.
Oliveira GMM et al., Cardiovascular Statistics - Brazil 2021. Arq Bras Cardiol. 2022 Jan;118(1):115-373. English, Portuguese. doi: 10.36660/abc.20211012. PMID: 35195219; PMCID: PMC8959063.
Packer, M., Anker, S. D., Butler, J., et al. (2020). Empagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine, 383(15), 1413–1424.
Perkovic, V., Jardine, M. J., Neal, B., et al. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine, 380(24), 2295–2306.
Renaud, S. J. et al. Sotagliflozin: A dual SGLT1/2 inhibitor for the treatment of diabetes and heart failure. Diabetes, Obesity and Metabolism, v. 21, n. 7, p. 1642-1651, 2019.
TAYLOR, C. J. et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: population-based cohort study. BMJ, v. 364, p. l223, 2019.
YANCY, C. W.; JESSUP, M.; BOZKURT, B. et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation, v. 136, n. 6, p. e137-e161, 2017.
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine, v. 383, n. 14, p. 1413-1424, 2020.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Davi Nogueira Jales, Maria Clara Barbosa de almeida, Cinobelina Pinheiro Elvas kronbauer, Evandro Cesar Bezerra Damasceno Junio, Sheylla Raquel Diniz Cavalcante Aguiar, Janaína Mendes Caldas sampaio, Emília Moura Silva, Ysa Bruna Araújo Gonçalves, Loara Oliveira Hellmann, Paulo Henrique Paes Landim Filho, Ana Sophia do Amaral Simões Carvalho
